Home/Hedge Fund Intelligence/Agios Pharmaceuticals, Inc.
Nasdaq: AGIOStockForm 13F30 Jun 2026

Hedge funds that hold Agios Pharmaceuticals, Inc. Nasdaq: AGIO

CUSIP 00847X104 · who reports it, how much, and how much it matters to them

26 of the 720 hedge fund managers we track reported shares of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) on Form 13F for 30 June 2026. Between them they reported USD 587m. The largest position belongs to Farallon Capital Management, at USD 220m. The manager with the most riding on it is Exome Asset Management, where it is 1.6% of the reported book.

Managers reporting it26of 720 we track
Value they reportUSD 587mshares only, 30 Jun 2026
Funds they run427with a file on PPLI.com
Largest positionUSD 220mFarallon Capital Management
Typical weight0.1%median share of a manager's book
Heaviest weight1.6%Exome Asset Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

26 managers, USD 587m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Agios Pharmaceuticals, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Farallon Capital Management56 funds on PPLI.comUSD 220m1.0%
2D. E. Shaw & Co.15 funds on PPLI.comUSD 115m0.1%
3Armistice Capital1 fund on PPLI.comUSD 89m1.1%
4Citadel Advisors32 funds on PPLI.comUSD 27m0.0%
5Two Sigma Investments35 funds on PPLI.comUSD 20m0.0%
6Rock Springs Capital Management2 funds on PPLI.comUSD 20m1.0%
7Schonfeld Strategic Advisors30 funds on PPLI.comUSD 19m0.1%
8POINT72 Asset Management17 funds on PPLI.comUSD 19m0.0%
9Squarepoint Ops7 funds on PPLI.comUSD 12m0.0%
10Palo Alto Investors6 funds on PPLI.comUSD 7.9m1.1%
11Boothbay Fund Management2 funds on PPLI.comUSD 5.6m0.1%
12Marshall Wace LLP84 funds on PPLI.comUSD 5.2m0.0%
13Arrowmark Colorado Holdings24 funds on PPLI.comUSD 4.4m0.2%
14Capital Fund Management S.A.12 funds on PPLI.comUSD 3.9m0.0%
15Jain Global1 fund on PPLI.comUSD 3.4m0.0%
16Campbell & Company Investment Adviser8 funds on PPLI.comUSD 2.7m0.1%
17Exome Asset Management2 funds on PPLI.comUSD 2.6m1.6%
18Edgestream Partners5 funds on PPLI.comUSD 2.6m0.1%
19Tudor Investment Corporation10 funds on PPLI.comUSD 2.4m0.0%
20Engineers Gate Manager1 fund on PPLI.comUSD 2m0.0%
21Aquatic Capital Management3 funds on PPLI.comUSD 1.4m0.0%
22The Quarry1 fund on PPLI.comUSD 748,0000.1%
23Hudson Bay Capital Management8 funds on PPLI.comUSD 360,0000.0%
24Brevan Howard Capital Management39 funds on PPLI.comUSD 345,0000.0%
25Capstone Investment Advisors25 funds on PPLI.comUSD 341,0000.0%
26Bayforest Capital1 fund on PPLI.comUSD 55,3680.1%
Next: where it matters most
Where it matters most

For Exome Asset Management it is 1.6% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Exome Asset ManagementUSD 2.6m1.6%
2Palo Alto InvestorsUSD 7.9m1.1%
3Armistice CapitalUSD 89m1.1%
4Farallon Capital ManagementUSD 220m1.0%
5Rock Springs Capital ManagementUSD 20m1.0%
6Arrowmark Colorado HoldingsUSD 4.4m0.2%
7Campbell & Company Investment AdviserUSD 2.7m0.1%
8Edgestream PartnersUSD 2.6m0.1%
9Boothbay Fund ManagementUSD 5.6m0.1%
10Schonfeld Strategic AdvisorsUSD 19m0.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Agios Pharmaceuticals, Inc.

What is the ticker symbol of Agios Pharmaceuticals, Inc.?

Agios Pharmaceuticals, Inc. trades under the symbol AGIO on the Nasdaq. Its CUSIP, the code used on Form 13F, is 00847X104.

Which hedge funds own Agios Pharmaceuticals, Inc. (Nasdaq: AGIO)?

26 of the 720 hedge fund managers PPLI.com tracks reported Agios Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Farallon Capital Management (USD 220m), D. E. Shaw & Co. (USD 115m), Armistice Capital (USD 89m), Citadel Advisors (USD 27m) and Two Sigma Investments (USD 20m).

How many hedge funds hold Agios Pharmaceuticals, Inc.?

26 managers in our coverage reported it, and between them they run 427 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Agios Pharmaceuticals, Inc.?

Exome Asset Management, where the position was 1.6% of the reported 13F book at 30 June 2026.

Does this show who is short Agios Pharmaceuticals, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Agios Pharmaceuticals, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.